Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
Australia and New Zealand Dialysis and Transplantation (ANZDATA) Registry, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
Clin J Am Soc Nephrol. 2023 Jul 1;18(7):920-929. doi: 10.2215/CJN.0000000000000155. Epub 2023 May 4.
Transplanted women have high rates of preeclampsia. However, determinants of preeclampsia and association with graft survival and function remain uncertain. We aimed to determine rates of preeclampsia and its association with kidney transplant survival and function.
This was a retrospective cohort study analyzing postkidney transplantation pregnancies (≥20 weeks gestation) from the Australia and New Zealand Dialysis and Transplant Registry (2000-2021). Graft survival was assessed in three models accounting for repeated pregnancies and episodes of preeclampsia.
Preeclampsia status was captured in 357 of 390 pregnancies and occurred in 133 pregnancies (37%). The percentage of pregnancies reported to have preeclampsia rose from 27% in 2000-2004 to 48% from 2018 to 2021. Reported prior exposure to calcineurin inhibitors was high overall and higher in women who had preeclampsia (97% versus 88%, P = 0.005). Seventy-two (27%) graft failures were identified after a pregnancy, with a median follow-up of 8.08 years. Although women with preeclampsia had higher median preconception serum creatinine concentration (1.24 [interquartile range, 1.00-1.50] versus 1.13 [0.99-1.36] mg/dl; P = 0.02), in all survival models, preeclampsia was not associated with higher death-censored graft failure. In multivariable analysis of maternal factors (age, body mass index, primary kidney disease and transplant-pregnancy interval, preconception serum creatinine concentration, era of birth event, and tacrolimus or cyclosporin exposure), only era and preconception serum creatinine concentration ≥1.24 mg/dl (odds ratio, 2.48; 95% confidence interval [CI], 1.19 to 5.18) were associated with higher preeclampsia risk. Both preconception eGFR <45 ml/min per 1.73 m 2 (adjusted hazard ratio [HR], 5.55; 95% CI, 3.27 to 9.44, P < 0.001) and preconception serum creatinine concentration ≥1.24 mg/dl (adjusted HR, 3.06; 95% CI, 1.77 to 5.27, P < 0.001) were associated with a higher risk of graft failure even after adjusting for maternal characteristics.
In this large and contemporaneous registry cohort, preeclampsia was not associated with worse graft survival or function. Preconception kidney function was the main determinant of graft survival.
移植女性子痫前期的发生率较高。然而,子痫前期的决定因素及其与移植物存活和功能的关系仍不确定。我们旨在确定子痫前期的发生率及其与肾移植存活和功能的关系。
这是一项回顾性队列研究,分析了澳大利亚和新西兰透析和移植登记处(2000-2021 年)的肾移植后妊娠(≥20 周妊娠)。在考虑到重复妊娠和子痫前期发作的三种模型中评估移植物存活。
在 390 次妊娠中,有 357 次记录了子痫前期状态,其中 133 次(37%)发生子痫前期。报告有子痫前期的妊娠百分比从 2000-2004 年的 27%上升到 2018-2021 年的 48%。总体而言,报告的钙调神经磷酸酶抑制剂先前暴露率较高,子痫前期患者的暴露率更高(97%对 88%,P=0.005)。在一次妊娠后,有 72 例(27%)发生移植物失功,中位随访时间为 8.08 年。尽管子痫前期患者的中位孕前血清肌酐浓度较高(1.24[四分位间距,1.00-1.50]对 1.13[0.99-1.36]mg/dl;P=0.02),但在所有生存模型中,子痫前期与更高的死亡为终点的移植物失功无关。在对母亲因素(年龄、体重指数、原发肾脏疾病和移植妊娠间隔、孕前血清肌酐浓度、出生时代和他克莫司或环孢素暴露)进行多变量分析时,只有时代和孕前血清肌酐浓度≥1.24mg/dl(比值比,2.48;95%置信区间[CI],1.19 至 5.18)与子痫前期风险增加相关。孕前 eGFR<45ml/min/1.73m 2(校正危险比[HR],5.55;95%CI,3.27 至 9.44,P<0.001)和孕前血清肌酐浓度≥1.24mg/dl(校正 HR,3.06;95%CI,1.77 至 5.27,P<0.001)与即使在调整了母亲特征后,移植物失功的风险仍较高相关。
在这项大型、同期登记队列研究中,子痫前期与移植物存活率或功能无不良关联。孕前肾功能是移植物存活率的主要决定因素。